Biogen to present new research data at AAN 2017

Biogen has announced plans to present data on a number of its newest neurological therapies at the forthcoming American Academy of Neurology (AAN) annual meeting in Boston.

The company will share data from its portfolio of treatments and investigational therapies for people with serious neurological and neurodegenerative diseases at the conference, which runs from April 22nd to 28th.

This will include new real-world evidence supporting the benefits of Tecfidera, the world's most prescribed oral medicine for multiple sclerosis, and Tysabri, which is the only high-efficacy treatment for the disease with more than ten years of clinical experience.

Additionally, new data will be shared that further demonstrates the clinically meaningful efficacy and favourable safety profile of the spinal muscular atrophy drug Spinraza, in addition to results from a phase Ib study of aducanumab, an investigational treatment for early Alzheimer's disease.

Alfred Sandrock, executive vice-president and chief medical officer at Biogen, said: "The data from our MS, SMA and Alzheimer's disease programmes reflect our desire to advance the understanding of these diseases and make a meaningful difference in the lives of patients."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.